Observational studyNeurology(R) neuroimmunology & neuroinflammation2022
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management.Neurology and therapy · 2025Article
- Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseases.European journal of neurology · 2024Observational
- Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience.Diagnostics (Basel, Switzerland) · 2024Article
- Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis.Heliyon · 2024Article
- Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.Human vaccines & immunotherapeutics · 2023Article
- Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.Frontiers in immunology · 2023Article
- Article
- Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 1 institution in 1 country.
David Reyes-LeivaFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.ORCID 0000-0001-6983-7130
Joaquín López-ContrerasFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Esther MogaFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Francesc Pla-JuncàFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Elionor Lynton-PonsFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Ricardo Rojas-GarciaFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.ORCID 0000-0003-1411-5573
Janina Turon-SansFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Luis QuerolFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.ORCID 0000-0002-4289-8264
Montse OliveFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.ORCID 0000-0001-5727-0165
Rodrigo Álvarez-VelascoFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Marta Caballero-ÁvilaFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.ORCID 0000-0001-9850-8504
Álvaro CarbayoFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Ana Vesperinas-CastroFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Pere DomingoFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Isabel IllaFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Eduard GallardoFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Elena Cortés-VicenteFrom the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain. ecortes@santpau.cat.
Universitat Autònoma de Barcelona · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEvidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe and able to induce humoral and cellular responses in patients with MG.
methodsWe performed an observational, longitudinal, prospective study including 100 patients with MG of a referral center for MG in our country, conducted from April 2021 to November 2021 during the vaccination campaign. The mRNA-1273 vaccine was scheduled for all participants. Blood samples were collected before vaccination and 3 months after a second dose. Clinical changes in MG were measured using the MG activities of daily life score at baseline and 1 week after the first and second doses. A surveillance of all symptoms of coronavirus disease 2019 (COVID-19) was conducted throughout the study. Humoral and cellular immune responses after vaccination were assessed using a spike-antibody ELISA and interferon gamma release assay in plasma. The primary outcomes were clinically significant changes in MG symptoms after vaccination, adverse events (AEs), and seroconversion and T-cell immune response rates.
resultsNinety-nine patients completed the full vaccination schedule, and 98 had 2 blood samples taken. A statistically significant worsening of symptoms was identified after the first and second doses of the mRNA-1273 vaccine, but this was not clinically relevant. Mild AEs occurred in 14 patients after the first dose and in 21 patients after the second dose. Eighty-seven patients developed a humoral response and 72 patients showed a T-cell response after vaccination. A combined therapy with prednisone and other immunosuppressive drugs correlated with a lower seroconversion ratio (OR = 5.97, 95% CI 1.46-24.09, DISCUSSION: Our findings indicate that the mRNA vaccination against COVID-19 is safe in patients with MG and show no negative impact on the disease course. Patients achieved high humoral and cellular immune response levels. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that patients with MG receiving the mRNA-1273 vaccine did not show clinical worsening after vaccination and that most of the patients achieved high cellular or immune response levels.
Indexed as
2019-nCoV Vaccine mRNA-1273COVID-19Myasthenia GravisAntibodies, ViralHumansImmunity, CellularImmunity, HumoralLongitudinal StudiesProspective StudiesSARS-CoV-2T-Lymphocytes2019-nCoV Vaccine mRNA-1273Antibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.